Tammie L S Benzinger

List of Publications by Year
in descending order

392 papers	26,511 citations	11908 72 h-index	9118 149 g-index
414 all docs	414 docs citations	414 times ranked	28047 citing authors

#	Article	IF	Citations
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.4	2
2	Network dysfunction in cognitively normal *APOE* Îµ4 carriers is related to subclinical tau. Alzheimer's and Dementia, 2022, 18, 116-126.	0.4	7
3	Amyloid Imaging in Dementia and Neurodegenerative Disease. , 2022, , 99-110.		1
4	Tau Imaging in Neurodegenerative Dementia. , 2022, , 111-120.		0
5	Beta-Amyloid Moderates the Relationship Between Cortical Thickness and Attentional Control in Middle- and Older-Aged Adults. Neurobiology of Aging, 2022, 112, 181-190.	1.5	3
6	Association of *BDNF* Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	4.5	15
7	Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 905-924.	1.2	3
8	Importance of CSF-based AÎ² clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. Communications Biology, 2022, 5, 98.	2.0	22
9	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
10	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of Disease, 2022, 166, 105662.	2.1	21
11	Deep residual inception encoderâ€decoder network for amyloid PET harmonization. Alzheimer's and Dementia, 2022, 18, 2448-2457.	0.4	10
12	Intracranial internal carotid artery calcification is not predictive of future cognitive decline. Alzheimer's Research and Therapy, 2022, 14, 32.	3.0	6
13	Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity. Journal of Alzheimer's Disease, 2022, 86, 1831-1848.	1.2	7
14	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	16
15	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
16	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
17	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	2.1	27
18	Effect of Race on Prediction of Brain Amyloidosis by Plasma AÎ²42/AÎ²40, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.5	63

#	Article	IF	Citations
19	Autosomal dominant and sporadic late onset Alzheimer's disease share a common *in vivo* pathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
20	The Value of Neuroimaging in Dementia Diagnosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 800-821.	0.4	2
21	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. Journal of Cognitive Neuroscience, 2021, 33, 279-302.	1.1	10
22	Cerebrospinal fluid AÎ²42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. Neurobiology of Aging, 2021, 98, 116-123.	1.5	7
23	Socioeconomic Status Mediates Racial Differences Seen Using the <scp>AT(N)</scp> Framework. Annals of Neurology, 2021, 89, 254-265.	2.8	42
24	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	1.7	7
25	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. Journal of Alzheimer's Disease, 2021, 79, 895-903.	1.2	5
26	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	1.2	4
27	Lack of association between acute stroke, post-stroke dementia, race, and Î²-amyloid status. NeuroImage: Clinical, 2021, 29, 102553.	1.4	12
28	Obesity and White Matter Neuroinflammation Related Edema in Alzheimerâ€™s Disease Dementia Biomarker Negative Cognitively Normal Individuals. Journal of Alzheimer's Disease, 2021, 79, 1801-1811.	1.2	18
29	Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3172-3186.	3.3	6
30	Deep learningâ€based T1â€enhanced selection of linear attenuation coefficients (DLâ€TESLA) for PET/MR attenuation correction in dementia neuroimaging. Magnetic Resonance in Medicine, 2021, 86, 499-513.	1.9	11
31	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. International Journal of Molecular Sciences, 2021, 22, 2931.	1.8	10
32	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27
33	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	3.7	66
34	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
35	Sex modifies APOE Îµ4 dose effect on brain tau deposition in cognitively impaired individuals. Brain, 2021, 144, 3201-3211.	3.7	31
36	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.5	17

#	Article	IF	Citations
37	Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Annals of Clinical and Translational Neurology, 2021, 8, 1096-1109.	1.7	8
38	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. Psychological Science, 2021, 32, 849-860.	1.8	8
39	Beyond the AJR: "MRI Signatures of Brain Age and Disease Over the Lifespan Based on a Deep Brain Network and 14‰468 Individuals Worldwide" American Journal of Roentgenology, 2021, 216, 1170-1170.	1.0	0
40	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures. Journal of Nuclear Medicine, 2021, , jnumed.120.254490.	2.8	6
41	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
42	Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706.	3.9	15
43	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nature Communications, 2021, 12, 5346.	5.8	43
44	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. BMJ Open, 2021, 11, e050820.	0.8	8
45	*In* *Vitro* and *In Vivo* Investigation of S1PR1 Expression in the Central Nervous System Using [^{3}H]CS1P1 and [^{11}C]CS1P1. ACS Chemical Neuroscience, 2021, 12, 3733-3744.	1.7	13
46	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	3.0	3
47	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	1.5	9
48	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834.	1.5	35
49	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.4	12
50	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
51	Dopamine D1–D3 receptor density may correlate with parkinson disease clinical features. Annals of Clinical and Translational Neurology, 2021, 8, 224-237.	1.7	12
52	Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT). Alzheimer Disease and Associated Disorders, 2021, 35, 164-168.	0.6	30
53	PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to *S. aureus* Infection. Molecular Imaging, 2021, 2021, 9982020.	0.7	5
54	In vitro characterization of [3H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter. European Journal of Pharmacology, 2021, 911, 174556.	1.7	2

#	Article	IF	Citations
55	Improved comparability between measurements of mean cortical amyloid plaque burden derived from different PET tracers using multiple regions‐of‐interest and machine learning. Alzheimer's and Dementia, 2021, 17, .	0.4	0
56	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. Journal of Neurochemistry, 2020, 152, 235-251.	2.1	17
57	Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1. Molecular Imaging and Biology, 2020, 22, 285-292.	1.3	5
58	Association between personality and tau-PET binding in cognitively normal older adults. Brain Imaging and Behavior, 2020, 14, 2122-2131.	1.1	21
59	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF-α in APOE4 carriers. Neurobiology of Aging, 2020, 86, 112-122.	1.5	22
60	Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults. Journal of Racial and Ethnic Health Disparities, 2020, 7, 269-280.	1.8	4
61	The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia. Journal of the International Neuropsychological Society, 2020, 26, 596-606.	1.2	23
62	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. Ageing Research Reviews, 2020, 57, 100994.	5.0	57
63	Comparison of [11C]-PBR28 Binding Between Persons Living With HIV and HIV-Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 244-251.	0.9	14
64	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	1.5	13
65	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	1.5	11
66	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	1.4	17
67	Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1. International Journal of Molecular Sciences, 2020, 21, 8860.	1.8	3
68	Comparison of the Ekblom-Bak Submaximal Test to a Maximal Test in a Cohort of Healthy Younger and Older Adults in the United States. Frontiers in Physiology, 2020, 11, 550285.	1.3	1
69	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Frontiers in Neurology, 2020, 11, 632.	1.1	52
70	Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease. Neurology, 2020, 95, e1554-e1564.	1.5	12
71	Falls Associate with Neurodegenerative Changes in ATN Framework of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 745-752.	1.2	11
72	Mapping language function with task-based vs. resting-state functional MRI. PLoS ONE, 2020, 15, e0236423.	1.1	29

#	Article	IF	Citations
73	Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neuro-Oncology Practice, 2020, 7, 656-667.	1.0	5
74	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 96, 233-245.	1.5	20
75	Association of sex and APOE Îµ4 with brain tau deposition and atrophy in older adults with Alzheimer's disease. Theranostics, 2020, 10, 10563-10572.	4.6	15
76	Relationships between bigâ€five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12038.	1.2	9
77	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. International Journal of Molecular Sciences, 2020, 21, 6047.	1.8	8
78	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. Alzheimer Disease and Associated Disorders, 2020, 34, 212-219.	0.6	14
79	Increases in periventricular white matter hyperintensities associate with Alzheimer disease biomarkers. Alzheimer's and Dementia, 2020, 16, e041286.	0.4	3
80	Brain network dysfunction associated with blood neurofilament light chain in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041586.	0.4	1
81	Tauopathy in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e041683.	0.4	0
82	APOE4 status influences the amyloid and tau relationship. Alzheimer's and Dementia, 2020, 16, e042093.	0.4	0
83	Socioeconomic status mediates racial differences seen using the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e043216.	0.4	0
84	Headâ€toâ€head comparison of [18F]MKâ€6240 and [18F]flortaucipir (AVâ€1451) in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2020, 16, e044688.	0.4	1
85	Anteâ€and postmortem tau in autosomal dominant and lateâ€onset Alzheimerâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 2475-2480.	1.7	10
86	Impact of 3-Dimensional Versus 2-Dimensional Image Distortion Correction on Stereotactic Neurosurgical Navigation Image Fusion Reliability for Images Acquired With Intraoperative Magnetic Resonance Imaging. Operative Neurosurgery, 2020, 19, 599-607.	0.4	3
87	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. Cerebral Cortex, 2020, 30, 5686-5701.	1.6	22
88	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 74, 1085-1095.	1.2	18
89	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. Journal of Alzheimer's Disease, 2020, 74, 1045-1055.	1.2	52
90	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31

#	Article	IF	Citations
91	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	1.4	24
92	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	15.2	351
93	Magnetic resonance safety assessment of a new trend: magnetic eyelashes. Journal of Applied Clinical Medical Physics, 2020, 21, 323-325.	0.8	0
94	In vivo Characterization of Four 18F-Labeled S1PR1 Tracers for Neuroinflammation. Molecular Imaging and Biology, 2020, 22, 1362-1369.	1.3	13
95	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 2020, 38, 1019-1029.	0.8	483
96	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.4	13
97	APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature, 2020, 581, 71-76.	13.7	705
98	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.4	47
99	Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease. , 2020, , 507-519.		0
100	Progression of Low-Grade Glioma During Pregnancy With Subsequent Regression Postpartum Without Treatment—A Case Report. Neurosurgery, 2019, 84, E430-E436.	0.6	2
101	High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology, 2019, 93, e1647-e1659.	1.5	514
102	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. Annals of Clinical and Translational Neurology, 2019, 6, 1423-1434.	1.7	22
103	Sex modulates the ApoE ϵ4 effect on brain tau deposition measured by ^{18}F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics, 2019, 9, 4959-4970.	4.6	50
104	Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use. Applied Radiation and Isotopes, 2019, 152, 30-36.	0.7	6
105	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	0.6	23
106	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. Annals of Neurology, 2019, 86, 616-625.	2.8	22
107	What are the threats to successful brain and cognitive aging?. Neurobiology of Aging, 2019, 83, 130-134.	1.5	20
108	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.4	7

#	Article	IF	Citations
109	Twoâ€period linear mixed effects models to analyze clinical trials with runâ€in data when the primary outcome is continuous: Applications to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 450-457.	1.8	2
110	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
111	Persistent metabolic youth in the aging female brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3251-3255.	3.3	133
112	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-Î² Burden in Cognitively Normal Individuals in Late-Life. Journal of Alzheimer's Disease, 2019, 69, 817-827.	1.2	23
113	The effect of ApoE Îµ4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. NeuroImage: Clinical, 2019, 22, 101795.	1.4	34
114	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	3.7	36
115	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
116	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101767.	1.4	41
117	Comparison of Pittsburgh compound B and florbetapir in crossâ€sectional and longitudinal studies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 180-190.	1.2	84
118	A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 1625-1633.	1.2	32
119	Structural signature of sporadic Creutzfeldtâ€"Jakob disease. European Journal of Neurology, 2019, 26, 1037-1043.	1.7	1
120	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. European Journal of Neurology, 2019, 26, 1235-1239.	1.7	3
121	Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 15-20.	0.6	11
122	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. Alzheimer's and Dementia, 2019, 15, 506-514.	0.4	28
123	Tau PET in autosomal dominant Alzheimerâ€™s disease: relationship with cognition, dementia and other biomarkers. Brain, 2019, 142, 1063-1076.	3.7	122
124	ICâ€Pâ€131: PIB BINDING TOPOGRAPHY BEST CORRELATES WITH YOUNG ADULT GLYCOLYSIS. Alzheimer's and Dementia, 2019, 15, P108.	0.4	0
125	ICâ€Pâ€094: CROSSâ€SECTIONAL AND LONGITUDINAL ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P82.	0.4	0
126	ICâ€Pâ€046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.4	0

#	Article	IF	Citations
127	IC–P–098: PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P85.	0.4	0
128	IC–P–177: MK–6240–PET NEUROFIBRILLARY TANGLE PATTERN SUBTYPES ARE ASSOCIATED WITH DISTINCT MEMORY AND COGNITIVE PERFORMANCE. Alzheimer's and Dementia, 2019, 15, P138.	0.4	0
129	Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. PLoS ONE, 2019, 14, e0225093.	1.1	0
130	IC–P–021: LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD. Alzheimer's and Dementia, 2019, 15, P29.	0.4	2
131	O3–12–01: ASSOCIATION BETWEEN SERUM NEUROFILAMENT LIGHT AND ESTABLISHED WHITE MATTER NEUROIMAGING MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P914.	0.4	0
132	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
133	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	2.8	23
134	Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Science Translational Medicine, 2019, 11, .	5.8	208
135	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	4.5	227
136	Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine, 2019, 25, 270-276.	15.2	987
137	Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals. Journal of Infectious Diseases, 2019, 220, 68-72.	1.9	12
138	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiology of Aging, 2019, 75, 42-50.	1.5	36
139	A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study. Journal of Applied Gerontology, 2019, 38, 277-289.	1.0	29
140	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain, 2018, 141, 1186-1200.	3.7	83
141	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer's and Dementia, 2018, 14, 1460-1469.	0.4	192
142	Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. JAMA Neurology, 2018, 75, 608.	4.5	19
143	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain, 2018, 141, 1486-1500.	3.7	79
144	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain, 2018, 141, 1828-1839.	3.7	99

#	Article	IF	Citations
145	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
146	In vivo [18 F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology, 2018, 90, e896-e906.	1.5	27
147	Cross€sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid Î² positron emission tomography pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 245-252.	1.2	49
148	Tau Kinetics in Neurons and the Human Central Nervous System. Neuron, 2018, 97, 1284-1298.e7.	3.8	381
149	Data-driven models of dominantly-inherited Alzheimer€™s disease progression. Brain, 2018, 141, 1529-1544.	3.7	111
150	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 67, 95-98.	1.5	73
151	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.4	42
152	Diffusion Tensor Imaging as a Biomarker to Differentiate Acute Disseminated Encephalomyelitis From Multiple Sclerosis at First Demyelination. Pediatric Neurology, 2018, 78, 70-74.	1.0	6
153	P1€487: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P514.	0.4	0
154	IC€P€195: QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEURO€MMNUE IMAGING. Alzheimer's and Dementia, 2018, 14, P161.	0.4	0
155	P3€494: EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES. Alzheimer's and Dementia, 2018, 14, P1311.	0.4	0
156	IC€P€204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P167.	0.4	1
157	FTS4€01€03: MRI AND PET ISSUES. Alzheimer's and Dementia, 2018, 14, P1399.	0.4	0
158	P3€439: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASIS€3 DATA. Alzheimer's and Dementia, 2018, 14, P1282.	0.4	0
159	P3€251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2018, 14, P1170.	0.4	1
160	P2€464: BIOLOGICAL CORRELATES OF WHITE MATTER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P899.	0.4	0
161	P4€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. Alzheimer's and Dementia, 2018, 14, P1472.	0.4	1
162	IC€P€158: GENETIC AND ENVIRONMENTAL FACTORS ARE DIFFERENTIALLY RELATED TO AÎ² BURDEN IN THE PRESYMPTOMATIC PHASE OF AUTOSOMAL DOMINANT AND SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P134.	0.4	0

#	Article	IF	Citations
163	ICâ€P â€167: ALTERED RESTINGâ€STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P140.	0.4	0
164	ICâ€P â€090: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. Alzheimer's and Dementia, 2018, 14, P75.	0.4	1
165	ICâ€P â€030: CSF SPDGFRB, A MEASURE OF VASCULAR DYSFUNCTION, IS RELATED TO DISRUPTED FUNCTIONAL CONNECTIVITY AMONG BRAIN REGIONS ASSOCIATED WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P34.	0.4	0
166	ICâ€P â€048: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES. Alzheimer's and Dementia, 2018, 14, P47.	0.4	0
167	P3â€380: ALTERED RESTINGâ€STATE FUNCTIONAL MRI SIGNAL ENTROPY IN TEMPORAL AND PARIETAL LOBES IN SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1239.	0.4	0
168	ICâ€P â€162: REGIONAL CORTICAL THINNING PATTERNS IN COGNITIVELY IMPAIRED AND CONVERTER INDIVIDUALS USING OASISâ€3 DATA. Alzheimer's and Dementia, 2018, 14, P136.	0.4	0
169	ICâ€P â€062: EVALUATING NEUROâ€IMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P57.	0.4	0
170	ICâ€P â€009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19.	0.4	0
171	ICâ€02â€01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2018, 14, P1.	0.4	0
172	ICâ€P â€042: RESTINGâ€STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P42.	0.4	0
173	ICâ€P â€067: THE BDNFVAL66MET SNP IS RELATED TO HIPPOCAMPAL CONNECTIVITY AND COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P60.	0.4	0
174	ICâ€P â€043: FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P43.	0.4	0
175	P1â€023: MASS SPECTROMETRYâ€"BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD. Alzheimer's and Dementia, 2018, 14, P273.	0.4	2
176	ICâ€P â€177: AGEâ€NORMED DIFFUSION BASIS SPECTRUM IMAGING (DBSI) CELL RATIOS TO ASSESS NEUROINFLAMMATION IN ALZHEIMER'S DISEASE CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P149.	0.4	0
177	The relevance of cerebrospinal fluid Î±-synuclein levels to sporadic and familial Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 130.	2.4	44
178	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 669-677.	1.2	14
179	ICâ€P â€164: OASISâ€3: LONGITUDINAL NEUROIMAGING, CLINICAL, AND COGNITIVE DATASET FOR NORMAL AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P138.	0.4	7
180	Depression and Alzheimerâ€™s Disease Biomarkers Predict Driving Decline. Journal of Alzheimer's Disease, 2018, 66, 1213-1221.	1.2	11

#	Article	IF	Citations
181	P2–436: PIB–PET NEUROIMAGING CORRELATES WITH β–AMYLOIDOSIS IN BOTH LATE–ONSET AND AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P881.	0.4	0
182	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 669-676.	1.8	9
183	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. Brain, 2018, 141, 3065-3080.	3.7	116
184	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
185	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	3.7	24
186	IC–04–02: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CORTICAL THICKNESS, BETA–AMYLOID BURDEN, AND CEREBRAL GLUCOSE METABOLISM IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P7.	0.4	0
187	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.5	193
188	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	1.5	42
189	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	1.4	76
190	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology, 2018, 91, e313-e318.	1.5	68
191	Integration of resting state functional MRI into clinical practice - A large single institution experience. PLoS ONE, 2018, 13, e0198349.	1.1	54
192	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology, 2018, 91, e859-e866.	1.5	190
193	Amyloid-β Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity. Frontiers in Neurology, 2018, 9, 169.	1.1	24
194	Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer's Disease. Geriatrics (Switzerland), 2018, 3, 23.	0.6	6
195	Effect of *BDNF* Val66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	2.8	25
196	Discovery and validation of autosomal dominant Alzheimer's disease mutations. Alzheimer's Research and Therapy, 2018, 10, 67.	3.0	29
197	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
198	Gaussian Processes with optimal kernel construction for neuro-degenerative clinical onset prediction. , 2018, , .		1

#	Article	IF	Citations
199	Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Disease and Associated Disorders, 2017, 31, 69-72.	0.6	34
200	Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 74-82.	1.8	44
201	Neurologic Applications of PET/MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2017, 25, 297-313.	0.6	36
202	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. Alzheimer Disease and Associated Disorders, 2017, 31, 87-93.	0.6	52
203	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.4	45
204	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Scientific Reports, 2017, 7, 1225.	1.6	42
205	The use of hippocampal volumetric measurements to improve diagnostic accuracy in pediatric patients with mesial temporal sclerosis. Journal of Neurosurgery: Pediatrics, 2017, 19, 720-728.	0.8	9
206	A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. NeuroImage, 2017, 147, 346-359.	2.1	200
207	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. NeuroImage, 2017, 148, 296-304.	2.1	52
208	Resting-state Functional Magnetic Resonance Imaging in Presurgical Functional Mapping. Neuroimaging Clinics of North America, 2017, 27, 621-633.	0.5	53
209	Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's and Dementia, 2017, 13, 841-849.	0.4	423
210	Loss of Brain Aerobic Glycolysis in Normal Human Aging. Cell Metabolism, 2017, 26, 353-360.e3.	7.2	228
211	A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neuroscience Letters, 2017, 657, 11-15.	1.0	9
212	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. NeuroImage, 2017, 161, 171-178.	2.1	116
213	[IC–P–057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
214	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 61, 509-513.	1.2	11
215	[P4–218]: YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1352.	0.4	0
216	The DIAN–TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's and Dementia, 2017, 13, 8-19.	0.4	230

#	Article	IF	Citations
217	Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation (N135Y) causing Alzheimer's disease. Neurobiology of Aging, 2017, 49, 216.e7-216.e13.	1.5	22
218	Quantitative hemodynamic PET imaging using image-derived arterial input function and a PET/MR hybrid scanner. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1435-1446.	2.4	19
219	[P2â€"372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.4	0
220	[P1â€"008]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P233.	0.4	0
221	[P4â€"244]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1370.	0.4	0
222	[ICâ€Pâ€054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P44.	0.4	0
223	[ICâ€Pâ€061]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P50.	0.4	0
224	[ICâ€Pâ€064]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
225	[ICâ€Pâ€138]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P105.	0.4	0
226	[ICâ€Pâ€166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.4	0
227	[ICâ€Pâ€205]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P149.	0.4	0
228	[ICâ€01â€02]: WHITE MATTER INTEGRITY REFLECTS TAU ACCUMULATION IN ADâ€DEFINED REGIONS. Alzheimer's and Dementia, 2017, 13, P1.	0.4	0
229	[ICâ€02â€02]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P4.	0.4	0
230	[P1â€"267]: BDNF VAL66MET INCREASES RATE OF MEMORY DECLINE, HIPPOCAMPAL VOLUME LOSS AND TAU ACCUMULATION IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P351.	0.4	0
231	[P1â€"402]: BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P427.	0.4	0
232	[P1â€"422]: RELATIONSHIP BETWEEN TAU POSITRON EMISSION TOMOGRAPHY WITH [18F]â€AVâ€1451 AND LONGITUDINAL CORTICAL ATROPHY IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P440.	0.4	0
233	[P2â€"209]: QUANTIFYING PRECLINICAL STAGES OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) AND THE ASSOCIATED OVERALL BIOMARKER SIGNATURE ACROSS MODALITIES USING THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN). Alzheimer's and Dementia, 2017, 13, P689.	0.4	0
234	[P2â€"345]: APOE4 EFFECT ON LONGITUDINAL VOLUMETRICS AND PIB ACCUMULATION IN PRECLINICAL ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P754.	0.4	0

#	Article	IF	Citations
235	[O1â€"02â€"01]: CORTICAL THINNING PATTERN IN AUTOSOMAL DOMINANT AD PREDICTS AMYLOID POSITIVITY IN SPORADIC AD. Alzheimer's and Dementia, 2017, 13, P184.	0.4	0
236	[O1â€"02â€"02]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P185.	0.4	0
237	[O1â€"02â€"03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
238	[O1â€"02â€"05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P187.	0.4	1
239	[S2â€"01â€"03]: TIME COURSE OF AMYLOID AND TAU DEPOSITION IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P541.	0.4	1
240	[O2â€"01â€"05]: IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE. Alzheimer's and Dementia, 2017, 13, P550.	0.4	0
241	[O2â€"05â€"03]: CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND <i>IN VIVO</i> AMYLOID IMAGING. Alzheimer's and Dementia, 2017, 13, P561.	0.4	0
242	[O3â€"09â€"05]: BRAIN AEROBIC GLYCOLYSIS AND TAU DEPOSITION WITH [18F]â€AVâ€1451 PET. Alzheimer's and Dementia, 2017, 13, P922.	0.4	0
243	[P4â€463]: PREDICTION OF INCIDENT DEMENTIA: LONGITUDINAL BIOMARKER AND CLINICAL CHANGES BEFORE AND AFTER. Alzheimer's and Dementia, 2017, 13, P1508.	0.4	0
244	[DTâ€01â€03]: CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA. Alzheimer's and Dementia, 2017, 13, P1475.	0.4	0
245	[O1â€"02â€"04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.4	0
246	Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficits.. Neuropsychology, 2017, 31, 708-723.	1.0	7
247	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	1.1	45
248	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future â€œNon-Cognitiveâ€ Outcomes of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 1055-1064.	1.2	8
249	ICâ€Pâ€117: Neuronal Injury and Degeneration Evaluated With Imaging and CSF Biomarkers in Autosomal Dominant AD: Results From The Dian Study. Alzheimer's and Dementia, 2016, 12, P87.	0.4	0
250	P1-221: Dynamic Relationships Between â€œBig Fiveâ€Personality Traits, Alzheimerâ€™s Disease Biomarkers, and Cognition in Autosomal Dominant Alzheimerâ€™s Disease. , 2016, 12, P491-P492.		0
251	P1â€254: Principal Component Analysis of [18F]â€Avâ€1451 TAU Pet in Alzheimerâ€™S Disease and Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P507.	0.4	0
252	ICâ€01â€03: Classifying TAU Pet Positivity With [18F]â€AVâ€1451 in Preclinical Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P2.	0.4	2

#	Article	IF	Citations
253	P3â€234: Similarities and Differences in Patterns of [F18]â€AVâ€1451 and [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P915.	0.4	0
254	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2016, 12, P145-P146.		0
255	ICâ€Pâ€206: Similarities and Differences in Patterns of [F18]â€Avâ€1451 And [F18]â€FDG in Frontotemporal Dementia. Alzheimer's and Dementia, 2016, 12, P147.	0.4	0
256	O2â€08â€05: Neuronal Injury and Degeneration Evaluated with Imaging and CSF Biomarkers in Autosomal Dominant Alzheimer's Disease: Results from the Dian Study. Alzheimer's and Dementia, 2016, 12, P246.	0.4	0
257	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 2016, 43, 23-33.	1.5	49
258	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
259	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. American Journal of Geriatric Psychiatry, 2016, 24, 1095-1104.	0.6	95
260	Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiology of Aging, 2016, 47, 201-209.	1.5	17
261	Longitudinal Î²-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Nonâ€"Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1192.	4.5	77
262	<i>BDNF</i>Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70
263	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between Î²-Amyloid and Tauopathy. JAMA Neurology, 2016, 73, 1070.	4.5	246
264	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Annals of Neurology, 2016, 80, 379-387.	2.8	82
265	Tau and AÎ² imaging, CSF measures, and cognition in Alzheimerâ€™s disease. Science Translational Medicine, 2016, 8, 338ra66.	5.8	560
266	Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. Journal of Alzheimer's Disease, 2016, 50, 887-894.	1.2	40
267	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain, 2016, 139, 2249-2260.	3.7	150
268	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	2.8	381
269	Clinical Resting-state fMRI in the Preoperative Setting. Topics in Magnetic Resonance Imaging, 2016, 25, 11-18.	0.7	63
270	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology, 2016, 86, 1499-1506.	1.5	39

#	Article	IF	Citations
271	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. Neurobiology of Aging, 2016, 38, 104-111.	1.5	15
272	Impact of MR-Based Attenuation Correction on Neurologic PET Studies. Journal of Nuclear Medicine, 2016, 57, 913-917.	2.8	28
273	Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activatorâ€"Eligible Stroke Patients When Clinical Impression Is Stroke Mimic. Stroke, 2016, 47, 1012-1017.	1.0	25
274	Heterogeneous Optimization Framework: Reproducible Preprocessing of Multi-Spectral Clinical MRI for Neuro-Oncology Imaging Research. Neuroinformatics, 2016, 14, 305-317.	1.5	6
275	Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics, 2016, 36, 1147-1163.	1.4	78
276	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. Journal of the International Neuropsychological Society, 2015, 21, 573-583.	1.2	29
277	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
278	IC-P-051: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P41-P41.		0
279	P2-138: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P538-P538.		0
280	IC-P-052: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PIB,Âand cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P41-P41.		0
281	P3-175: The ilp: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P697-P697.		0
282	Beyond the <scp>CA</scp>1 subfield: Local hippocampal shape changes in <scp>MRI</scp>â€"negative temporal lobe epilepsy. Epilepsia, 2015, 56, 780-788.	2.6	25
283	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp>lzheimer <scp>D</scp>isease <scp>N</scp>euroimaging <scp>I</scp>nitiative (<scp>ADNI</scp>) and the <scp>D</scp>ominantly <scp>I</scp>nherited <scp>A</scp>lzheimer <scp>N</scp>etwork (<scp>DIAN</scp>). Neuropathology, 2015, 35, 390-400.	0.7	68
284	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.. Neuropsychology, 2015, 29, 368-381.	1.0	24
285	IC-P-100: The ILP: A new tool for evaluating preclinical Alzheimer's disease using volumetric MRI in a single participant. , 2015, 11, P68-P68.		1
286	IC-03-02: Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication. , 2015, 11, P8-P9.		0
287	P2-085: Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers. , 2015, 11, P516-P516.		2
288	Age and amyloid effects on human central nervous system amyloidâ€beta kinetics. Annals of Neurology, 2015, 78, 439-453.	2.8	148

#	Article	IF	Citations
289	In response: From the CA1 subfield, and beyond!. Epilepsia, 2015, 56, 1471-1472.	2.6	0
290	Amyloid Burden in Cognitively Normal Elderly is Associated with Preferential Hippocampal Subfield Volume Loss. Journal of Alzheimer's Disease, 2015, 45, 27-33.	1.2	44
291	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. PLoS ONE, 2015, 10, e0122920.	1.1	30
292	Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Disease Markers, 2015, 2015, 1-11.	0.6	25
293	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. NeuroImage: Clinical, 2015, 8, 246-252.	1.4	43
294	P3-132: Comparison of cerebral glucose metabolism 18 F-FDG, early frames of 11 C-PiB, and cerebral blood flow 15 O-H2 O in autosomal dominant Alzheimer's disease. , 2015, 11, P674-P674.		0
295	IC-P-164: Patterns of tau binding in T807-PET imaging. , 2015, 11, P110-P110.		1
296	P2-154: Patterns of tau binding in T807-PET imaging. , 2015, 11, P546-P546.		0
297	O2-01-03: Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence. , 2015, 11, P172-P172.		0
298	O5-06-06: Age-related decreases in tracer influx rate measured with PiB PET. , 2015, 11, P330-P330.		0
299	Probabilistic Air Segmentation and Sparse Regression Estimated Pseudo CT for PET/MR Attenuation Correction. Radiology, 2015, 275, 562-569.	3.6	27
300	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.4	603
301	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurology, 2015, 72, 1029.	4.5	237
302	MR-based attenuation correction for PET/MRI neurological studies with continuous-valued attenuation coefficients for bone through a conversion from R2* to CT-Hounsfield units. NeuroImage, 2015, 112, 160-168.	2.1	79
303	Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. Cognitive, Affective and Behavioral Neuroscience, 2015, 15, 625-643.	1.0	36
304	Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. Neurology, 2015, 84, 1254-1260.	1.5	65
305	Whipple's Disease Masquerades as Dementia With Lewy Bodies. Alzheimer Disease and Associated Disorders, 2015, 29, 85-89.	0.6	7
306	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiology of Aging, 2015, 36, 1771-1779.	1.5	36

#	Article	IF	Citations
307	The role of imaging in the management of adults with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 457-479.	1.4	81
308	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27
309	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	2.1	188
310	Susceptibility-Weighted Imaging Helps to Discriminate Pediatric Multiple Sclerosis From Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2015, 52, 36-41.	1.0	12
311	Pathological Correlates of White Matter Hyperintensities on Magnetic Resonance Imaging. Dementia and Geriatric Cognitive Disorders, 2015, 39, 92-104.	0.7	77
312	Weighted brain networks in disease: centrality and entropy in human immunodeficiency virus and aging. Neurobiology of Aging, 2015, 36, 401-412.	1.5	45
313	Decreased Platelet APP Isoform Ratios in Autosomal Dominant Alzheimer's Disease: Baseline Data from a DIAN Cohort Subset. Current Alzheimer Research, 2015, 12, 157-164.	0.7	10
314	NI-25 * PHYSIOLOGIC IMAGING IN PATIENTS WITH BRAIN METASTASES; HETEROGENEITY BASED UPON PRIMARY TUMOR SUBTYPE. Neuro-Oncology, 2014, 16, v143-v143.	0.6	0
315	Allodynia and Descending Pain Modulation in Migraine: A Resting State Functional Connectivity Analysis. Pain Medicine, 2014, 15, 154-165.	0.9	120
316	Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. Science Translational Medicine, 2014, 6, 226ra30.	5.8	320
317	The Effect of APOE Îµ4 Allele on Cholinesterase Inhibitors in Patients With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 122-127.	0.6	21
318	A Novel PSEN1 Mutation (I238M) associated with Early-Onset Alzheimer's Disease in an African-American Woman. Journal of Alzheimer's Disease, 2014, 40, 271-275.	1.2	14
319	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	4.5	112
320	Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 757-768.	1.5	318
321	The evolving role of neurological imaging in neuro-oncology. Journal of Neuro-Oncology, 2014, 119, 491-502.	1.4	2
322	Comparison of Perfusion- and Diffusion-weighted Imaging Parameters in Brain Tumor Studies Processed Using Different Software Platforms. Academic Radiology, 2014, 21, 1294-1303.	1.3	8
323	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. Neurology, 2014, 83, 1613-1619.	1.5	51
324	Automated Classification of Radiology Reports to Facilitate Retrospective Study in Radiology. Journal of Digital Imaging, 2014, 27, 730-736.	1.6	15

#	Article	IF	Citations
325	Regional variability in Alzheimer's disease biomarkers. Future Neurology, 2014, 9, 131-134.	0.9	6
326	The Comprehensive Neuro-Oncology Data Repository (CONDR). Neurosurgery, 2014, 74, 88-98.	0.6	8
327	IC-P-094: ALTERED FMRI ACTIVATION PATTERN DURING VISUAL SCENE ENCODING IN AFFECTED AND NON-AFFECTED CARRIERS OF PSEN1 AND APP MUTATIONS. , 2014, 10, P53-P53.		1
328	P4-105: ALTERED FMRI ACTIVATION PATTERN DURING VISUAL SCENE ENCODING IN AFFECTED AND NON-AFFECTED CARRIERS OF PSEN1 AND APP MUTATIONS. , 2014, 10, P822-P823.		0
329	IC-P-148: ALTERED TASK-EVOKED FMRI ACTIVITY IN PRECLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P85-P85.		0
330	Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System. PLoS ONE, 2014, 9, e89998.	1.1	44
331	Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2013, 260, 498-506.	1.8	38
332	Effects of Aging and Alzheimer's Disease Along the Longitudinal Axis of the Hippocampus. Journal of Alzheimer's Disease, 2013, 37, 41-50.	1.2	32
333	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	3.3	309
334	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue Neurologique, 2013, 169, 737-743.	0.6	122
335	Improved in vivo diffusion tensor imaging of human cervical spinal cord. NeuroImage, 2013, 67, 64-76.	2.1	72
336	Impaired and facilitated functional networks in temporal lobe epilepsy. NeuroImage: Clinical, 2013, 2, 862-872.	1.4	111
337	Cerebrospinal Fluid Aβ42, Phosphorylated Tau$_{181}$, and Resting-State Functional Connectivity. JAMA Neurology, 2013, 70, 1242-8.	4.5	89
338	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.5	67
339	Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults.. Neuropsychology, 2013, 27, 516-528.	1.0	42
340	Alterations in Cerebral Oxygen Metabolism after Traumatic Brain Injury in Children. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 48-52.	2.4	27
341	Preclinical Alzheimer disease and risk of falls. Neurology, 2013, 81, 437-443.	1.5	69
342	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.5	174

#	Article	IF	Citations
343	Noninvasive Estimation of the Arterial Input Function in Positron Emission Tomography Imaging of Cerebral Blood Flow. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 115-121.	2.4	45
344	Low-Frequency Repetitive Transcranial Magnetic Stimulation to the Temporoparietal Junction for Tinnitus. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 388.	1.2	41
345	Increased in Vivo Amyloid-Î²42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Science Translational Medicine, 2013, 5, 189ra77.	5.8	196
346	Atypical Restingâ€State Functional Connectivity of Affective Pain Regions in Chronic Migraine. Headache, 2013, 53, 737-751.	1.8	156
347	Predicting a multi-parametric probability map of active tumor extent using random forests. , 2013, 2013, 6478-81.		7
348	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology, 2013, 80, 1784-1791.	1.5	194
349	Diffusion tensor MRI as a biomarker in axonal and myelin damage. Imaging in Medicine, 2013, 5, 427-440.	0.0	257
350	Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers. Current Alzheimer Research, 2013, 10, 790-796.	0.7	30
351	Quantitative Analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE, 2013, 8, e73377.	1.1	192
352	Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression. Journal of Neuroscience, 2012, 32, 8890-8899.	1.7	510
353	Exercise Engagement as a Moderator of the Effects of <emph type="ital">APOE</emph> Genotype on Amyloid Deposition. Archives of Neurology, 2012, 69, 636.	4.9	235
354	Susceptibility-Weighted Imaging: A New Tool in the Diagnosis and Evaluation of Abnormalities of the Vein of Galen in Children. American Journal of Neuroradiology, 2012, 33, 1747-1751.	1.2	17
355	Depression of whole-brain oxygen extraction fraction is associated with poor outcome in pediatric traumatic brain injury. Pediatric Research, 2012, 71, 199-204.	1.1	20
356	Developing an international network for Alzheimerâ€™s research: the Dominantly Inherited Alzheimer Network. Clinical Investigation, 2012, 2, 975-984.	0.0	180
357	Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1259-1268.	1.4	48
358	Î²-Amyloid Dynamics in Human Plasma. Archives of Neurology, 2012, 69, 1591.	4.9	61
359	<sup>11</sup>C-PiB Imaging of Human Immunodeficiency Virusâ€"Associated Neurocognitive Disorder. Archives of Neurology, 2012, 69, 72.	4.9	72
360	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	13.9	3,005

#	Article	IF	Citations
361	Alzheimer disease family history impacts resting state functional connectivity. Annals of Neurology, 2012, 72, 571-577.	2.8	65
362	PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 370-379.	1.8	132
363	Diminished performance on neuropsychological testing in late life depression is correlated with microstructural white matter abnormalities. NeuroImage, 2012, 60, 2182-2190.	2.1	60
364	Surgery and the Plastic Brain. Anesthesiology, 2012, 116, 510-512.	1.3	6
365	Accuracy of Susceptibility-Weighted Imaging for the Detection of Arteriovenous Shunting in Vascular Malformations of the Brain. Stroke, 2011, 42, 87-92.	1.0	71
366	Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. NeuroImage, 2011, 55, 1454-1460.	2.1	317
367	Neuropathologic Correlates for Diffusion Tensor Imaging in Postinfectious Encephalopathy. Pediatric Neurology, 2011, 44, 389-393.	1.0	15
368	Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study. Archives of Neurology, 2011, 68, 1313.	4.9	55
369	Cerebrospinal Fluid Biomarkers, Education, Brain Volume, and Future Cognition. Archives of Neurology, 2011, 68, 1145.	4.9	42
370	Amyloidâ€beta plaque growth in cognitively normal adults: Longitudinal [¹¹C]Pittsburgh compound B data. Annals of Neurology, 2011, 70, 857-861.	2.8	131
371	Reply to: Fractional synthesis and clearance rates for amyloid Î². Nature Medicine, 2011, 17, 1179-1180.	15.2	3
372	Postcontrast Susceptibility-Weighted Imaging. Stroke, 2011, 42, 3127-3131.	1.0	19
373	Serotonin signaling is associated with lower amyloid-Î² levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14968-14973.	3.3	281
374	Spinal Cord Ring Enhancement in Multiple Sclerosis. Archives of Neurology, 2010, 67, 1395-8.	4.9	30
375	Long-Term Prognosis of Pediatric Patients With Relapsing Acute Disseminated Encephalomyelitis. Journal of Child Neurology, 2010, 25, 681-688.	0.7	35
376	APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF AÎ²42. Journal of Neuroscience, 2010, 30, 17035-17040.	1.7	413
377	Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology, 2009, 72, 589-594.	1.5	98
378	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Î² in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.9	188

#	Article	IF	Citations
379	Diffuse Microstructural Abnormalities of Normal-Appearing White Matter in Late Life Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry, 2009, 66, 245-252.	0.7	124
380	MO-EE-A4-04: Quantitative Measurement of Hypoxia in Human Brain Tumors Using QBOLD MRI. Medical Physics, 2009, 36, 2706-2706.	1.6	0
381	The Use of Magnetic Resonance Diffusion Biomarkers to Predict Functional Outcome in Mild Traumatic Brain Injury. Neurosurgery, 2008, 62, 1410-1411.	0.6	0
382	Directional diffusivity as a magnetic resonance (MR) biomarker in demyelinating disease. Proceedings of SPIE, 2007, , .	0.8	1
383	pH dependent self assembly of Î²-amyloid(10-35) and Î²-amyloid(10-35)-PEG3000. Journal of Applied Crystallography, 2000, 33, 535-539.	1.9	43
384	Two-Dimensional Structure of Î²-Amyloid(10â˜³5) Fibrilsâ€. Biochemistry, 2000, 39, 3491-3499.	1.2	208
385	Structure of the Î²-Amyloid(10-35)Fibril. Journal of the American Chemical Society, 2000, 122, 7883-7889.	6.6	232
386	Self-Assembly of AÎ²(10-35)-PEG Block Copolymer Fibrils. Journal of the American Chemical Society, 1999, 121, 7429-7430.	6.6	148
387	Dipolar recoupling NMR of biomolecular self-assemblies: determining inter- and intrastrand distances in fibrilized Alzheimer's Î²-amyloid peptide. Solid State Nuclear Magnetic Resonance, 1998, 13, 149-166.	1.5	85
388	C-Terminal PEG Blocks the Irreversible Step in Î²-Amyloid(10-35) Fibrillogenesis. Journal of the American Chemical Society, 1998, 120, 7655-7656.	6.6	156
389	Structureâˆ'Function Relationships in Side Chain Lactam Cross-Linked Peptide Models of a Conserved N-Terminal Domain of Apolipoprotein Eâ€. Biochemistry, 1998, 37, 13222-13229.	1.2	9
390	Propagating structure of Alzheimer's Â-amyloid(10-35) is parallel Â-sheet with residues in exact register. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13407-13412.	3.3	429
391	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.4	2
392	Assessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease. OTJR Occupation, Participation and Health, 0, , 153944922211007.	0.4	0